生物处理优化和数字生物制造：全球市场
报告亮点
The global market for bioprocess optimization and digital biomanufacturing will grow from nearly $26.5 billion in 2018 to nearly $40.5 billion by 2023 with a compound annual growth rate (CAGR) of 8.9% for the period of 2018-2023.
报告包括
- 91个数据表和30个其他表
- 全球生物过程优化和数字生物制造（DM）的概述
- 评估DM过程分析技术（PAT）的作用
- A look into the new developments, new product launches and regulatory aspects in the global market
- 讨论影响DM在药品中采用DM的关键问题以及DM Technologies中的新兴趋势
- Detailed analysis of industry 4.0 in DM
- 该行业中市场参与者的全面概况，包括Agilent Technologies，Thermo Fisher Scientific Inc.，Waters Corp.，Shimadzu Corp.，Sartorius Stedium Biotech GmbH，GE Healthcare和ABB Ltd.
报告范围
The biggest challenge for a biopharmaceutical company is to produce a high-quality product in a cost-effective manner. The need to harness the first-to-market advantage as well as meet the growing pressure to control costs from consumers, insurance companies and governments has led many biopharmaceutical manufacturers to resort to innovative methods of production. Implementation of process intensification (continuous manufacturing) and use of disposable technologies has significantly boosted the production productivities. Integration of statistical modeling with standard bioprocess optimization methods has also been a positive strategy in achieving the goals of faster production time and better process design.
There is a growing demand from the FDA and other regulatory authorities to comply with the stringent regulatory guidelines of quality and traceability. There is humongous amount of data generated at every step of pharmaceutical manufacturing, including research and development, pilot plant and commercial manufacturing. Various automation systems at the company and at the contract manufacturing sites also generate large amounts of information. The resulting non-standard nomenclature and varying data structures complicate the communication systems, thereby delaying product release. Digital manufacturing (DM) is coming to transform pharmaceutical manufacturing in a big way. The connection between equipment, materials and people brought about by IIoT as well as data analytics platforms are leading to more efficient and faster processes.
BCC研究的新报告“生物过程优化和数字乐动体育-西甲2019赞助商生物制造：全球市场”提供了对全球环境中生物制作优化和数字生物制造市场的全面分析，包括2023年的市场预测和销售。市场将其细分为最重要的技术和解决方案，即制造技术，分析和过程控制技术以及软件。这些段中的每个段都被细分为不同的类型（如稍后所述）。这项研究调查了包括北美，欧洲和新兴市场在内的所有地理区域的生物过程优化和数字生物制造市场。新兴市场领域包括印度，中国，韩国，台湾，非洲，澳大利亚，新西兰，加拿大，拉丁美洲等地区。数字生物制造在生物过程优化，生物制造和柔性制造中的应用也已得到处理。
该报告讨论了影响DM在药品中采用的关键问题，以及DM技术的新兴趋势。它还以全球市场的新开发项目和新产品推出为特色。
该报告提供了相关的专利分析和行业市场参与者的全面概况。行业结构一章的重点是不断变化的市场趋势，重要的制造商和供应商及其市场份额和产品。本章还涵盖了合并和收购以及在本报告评估期间发生的任何其他合作或合作伙伴，预计将塑造该行业。
BCC Research’s new report elaborates on the strengths, weaknesses, threats and opportunities of the global bioprocess optimization and DM market. Any regulatory changes or new initiatives are highlighted.
该报告不包括数字制造在与药品无关的技术其他方面的应用。此外，重点是生物制药市场，而不是小分子药物。
分析师证书
Kamna Jhamb博士拥有13年以上的研究经验，其中超过四年专门用于市场研究。在进入市场研究领域之前，她曾在劳伦斯·伯克利国家实验室（Lawrence Berkeley National Lab）担任研究助理。拥有博士学位在微生物技术中，她在微生物学，蛋白质化学和分子生物学领域具有广泛的知识。她在知名的期刊上有几个国际出版物。对于BC乐动体育-西甲2019赞助商C研究，Kamna博士撰写了报告，涵盖了从医疗保健，金融到生物技术的主题。